Expands Foot & Ankle Portfolio, Boosts ASC Market Presence
Zimmer Biomet (NYSE: ZBH) announced plans to acquire Paragon 28 (NYSE: FNA) for $1.2 billion, expanding its foot and ankle offerings. The deal, expected to close in H1 2025, aligns with Zimmer Biomet’s growth strategy beyond core orthopedics.
Key Details:
- Paragon 28’s Strengths: Specializes in fracture, trauma, deformity correction, and joint replacement.
- Zimmer Biomet’s Strategy: Targets high-growth musculoskeletal segments and ambulatory surgery center (ASC) opportunities.
- Market Reaction: FNA shares surged 8% to $13.02, while ZBH dipped to $111.50.
Analyst Insights:
- BTIG (Buy Rating): Sees strong ASC synergies but notes talent retention challenges.
- Needham (Hold Rating): Predicts EPS dilution but expects more M&A in robotics, AI, and sports medicine.
Follow MEDWIRE.AI for the latest in medical device M&A.
